
AroCell Q2 - First quarter with a positive cash flow

Redeye is encouraged to see AroCell recording its first quarter with a positive cash flow, and the report solidifies our take on the coming quarters. We learn about a coming strategic overview that could entail an acquisition, but nothing concrete has been announced. We leave our base case intact and point to AroCell trading at undeservedly low EV/sales multiples.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[AroCell Q2 - First quarter with a positive cash flow](#)